Our Story

Our company

ForCast Ortho

ForCast Orthopedics was founded in 2017 by an experienced med-tech entrepreneur and a leading orthopedic surgeon. We are dedicated to the development of devices for targeted drug delivery to improve patient outcomes. Our lead indication automates a research method that has been clinically demonstrated to achieve superior patient outcomes compared with the standard of care for orthopedic, Periprosthetic Joint Infections (PJI). We believe our drug delivery implant will become the new gold standard in treatment replacing inadequate current methods, which suffer from low success rates, high cost and high patient morbidity including the risk of amputation.

RIDDS Illustration


A New Treatment Paradigm for targeted antiobiotic therapy

  • All current therapies do not consistently achieve intraarticular antibiotic. concentrations high enough to reach the Minimum Biofilm Eradication Concentration (MBEC) over time.This is seen as the primary cause of high failure rates in SOC treatments.
  • Dr. Leo Whiteside has proven Intraarticular Antibiotic Infusion (IAI) achieves superior patient outcomes compared to SOC treatment.
  • ForCast’s scientific analysis proves alignment of Dr. Whiteside’s patient outcomes with achieving MBEC concentrations.
  • ForCast’s new treatment platform simplifies and automates IAI as targeted antibiotic therapy for patients.


Since 2010, manual IAI has achieved superior patient outcomes used in 1-Stage and DAIR procedures. Yet, this research procedure has not been widely adopted due to patient/MD burden and its “off label” status today.

REGULATORY STATUS                         

ForCast Orthopedics’ Antibiotic Dispensing Knee (ADK) Spacer and Remote Implantable Drug Delivery System (RIDDS) have not yet been reviewed or cleared for use in the United States by the Food and Drug Administration. These products are currently not available for sale. This site is a solicitation for investment and corporate relationships.



Peter Noymer, PhD

Executive Chairman and CEO: Peter brings to ForCast a depth of experience leading life science startups through the development and commercialization of innovative products. His focus has been in areas of high unmet medical need across a variety of therapeutic areas, primarily where novel technologies can have a meaningful impact on patient care and outcomes. He holds MS and PhD degrees from MIT and a BS degree from Princeton University.

Jared Foran, MD

CSO, Co-Founder: Jared is a prominent orthopedic surgeon with over 17 years in practice specializing in total hip and knee replacement. He is a thought leader in the orthopedic community and the inventor of ForCast's ADK-Spacer. He is Director of Total Joint Replacement at St Anthony Hospital, OrthoColorado Hospital and a Partner at Panorama Orthopedics.

Jeff Castleberry, MBA

Co-Founder: Jeff leads with over 30 years of experience in med-device commercialization of new technologies and devices. His previous experience includes EndoShape, CardioOptics (acquired by Olympus), Larren (acquired by Battelle) and Vitalmetrics (acquired by Medtronic).

Ethan Mann, PhD

Ethan is a recognized expert in biofilm research. He trained as a post-doctoral fellow in infectious disease at the Ohio State University where he studied how bacteria cause medical device-related infections. Ethan also has an MBA from the University of Colorado and serves on NIH review panels.

Advisory Board

Leo Whiteside, MD

KOL, Leading Orthopedic Surgeon, Missouri Bone & Joint Institute Pioneer and world's leading researcher of Intraarticular Antibiotic Injection (IAI) for PJI treatment

Jeff DesJardin, MD

KOL, Infectious Disease Specialist, Western Infectious Disease Consultants

Carl Deirmengian, MD

KOL, Leading Orthopedic Surgeon, Rothman Orthopedic Institute CMO & Co-Founder of CD Diagnostics (acquired by Zimmer-Biomet), Venture Partner at BioStar Ventures

Richard Berger, MD

KOL, Leading Orthopedic Surgeon Assistant Professor, Rush University Medical Center


ForCast Orthopedics, Inc.
Longmont, CO